Unresectable or Metastatic Pancreatic Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Unresectable or metastatic pancreatic cancer (LAPC) is an advanced stage where the tumor cannot be completely removed through surgery or has spread to other body parts. Patients with LAPC often experience significant symptom burdens related to their primary malignancy. These symptoms may include pain, pancreatic insufficiency (resulting in difficulty digesting food), biliary obstruction (causing jaundice and related symptoms), and early satiety or gastric outlet obstruction (leading to feeling full quickly or difficulty eating). Most patients with pancreatic cancer are diagnosed at an advanced stage, with approximately 50% having metastatic disease and 25% to 35% having borderline or locally advanced disease. In terms of treatment options, gemcitabine plus nab-paclitaxel or FOLFIRINOX are commonly used as first-line chemotherapy regimens for patients with locally advanced or metastatic pancreatic cancer. Gemcitabine plus nab-paclitaxel has a median overall survival of 8.5 months, while FOLFIRINOX has a median survival of 11.1 months. Only a small percentage, fewer than 10%, of patients with pancreatic cancer have tumors that are potentially curable through surgical resection.
• In the USA, approximately 64,050 individuals will receive a pancreatic cancer diagnosis, with about 33,130 being men and 30,920 being women. Moreover, around 50,550 will die of pancreatic cancer, comprising 26,620 men and 23,930 women.

Thelansis’s “Unresectable or Metastatic Pancreatic Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Unresectable or Metastatic Pancreatic Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Unresectable or Metastatic Pancreatic Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Unresectable or Metastatic Pancreatic Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Unresectable or Metastatic Pancreatic Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Unresectable or Metastatic Pancreatic Cancer, Unresectable or Metastatic Pancreatic Cancer market outlook, Unresectable or Metastatic Pancreatic Cancer competitive landscape, Unresectable or Metastatic Pancreatic Cancer market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)